Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Staying on anticoagulation therapy significantly cuts death risk in AFib patients over 80, a new study finds. Analyzing over 45,000 older adults, researchers found those who never received the therapy were more than twice as likely to die within a year compared to those who continued it. GI bleeding was more common in treated patients, but the survival benefit remains compelling.
A large real-world study is pushing back against the tendency to withhold blood thinners from elderly atrial fibrillation (AFib) patients out of bleeding concerns. Researchers analyzed data from over 45,000 adults aged 80 and older with AFib and found that continuing anticoagulation therapy was associated with a 25% lower risk of death from any cause compared to never receiving it.
The survival gap was especially stark at the one-year mark — patients who never received anticoagulation were more than twice as likely to die as those who stayed on therapy. Even patients who discontinued treatment fared worse than those who continued, reinforcing the value of sustained use in appropriately selected older patients.
By the Numbers:
Why it matters: Age alone shouldn't be a reason to deny older AFib patients anticoagulation. This study reinforces that the mortality benefit of staying on therapy outweighs bleeding risks for appropriately selected patients — a critical reminder for clinicians managing this high-risk population.
